Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 13/20 | 0.80 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.58 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7141653 | 0.96 | LTA4H (0.80) | LTA4HS1PR1NPC1HTTRAB9A | |
| SCHEMBL7139967 | 0.93 | LTA4H (0.77) | LTA4HS1PR1S1PR3L3MBTL1 | |
| SCHEMBL7139678 | 0.90 | LTA4H (0.66) | LTA4HS1PR1NPC1HTTRAB9A | |
| SCHEMBL7132986 | 0.89 | LTA4H (1.00) | LTA4HS1PR1S1PR3S1PR5L3MBTL1 | |
| SCHEMBL7137987 | 0.88 | LTA4H (0.98) | LTA4HS1PR1S1PR3S1PR5L3MBTL1 | |
| SCHEMBL7140971 | 0.86 | LTA4H (0.65) | LTA4HS1PR1NPC1HTTRAB9A | |
| SCHEMBL7135460 | 0.86 | LTA4H (1.00) | LTA4HS1PR1NPC1HTTRAB9A | |
| SCHEMBL7139744 | 0.85 | LTA4H (1.00) | LTA4HS1PR1S1PR3 | |
| SCHEMBL7139455 | 0.84 | LTA4H (0.92) | LTA4HS1PR1NPC1S1PR3S1PR5 | |
| SCHEMBL18596907 | 0.82 | LTA4H (0.62) | LTA4HS1PR1NPC1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1221441-A2 | LTA4 Hydrolase inhibitors | G.D. SEARLE & CO. (US) | 2002-07-10 | — | — | EP | claimed |
| EP-0804427-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | claimed |
| EP-0786992-A2 | LTA 4? HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1997-08-06 | — | — | EP | claimed |
| WO-1996010999-A2 | LTA4 HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | claimed |
| WO-1996011192-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | claimed |
| US-6506876-B1 | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use | G.D. SEARLE & CO. | 2003-01-14 | — | — | US | disclosed |
| EP-0804427-B1 | LTA4 HYDROLASE INHIBITORS | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1221441-A2 | LTA4 Hydrolase inhibitors | G.D. SEARLE & CO. (US) | 2002-07-10 | — | — | EP | disclosed |
| EP-0804427-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0786992-A2 | LTA 4? HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1997-08-06 | — | — | EP | disclosed |
| US-5585492-A | USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES WHICH ARE MEDIATED BY LTB4 PRODUCTION, SUCH AS PSORIASIS, ULCERATIVE COLITIS, IRRITABLE BOWEL DISEASE AND ASTHMA | G. D. SEARLE & CO. (US) | 1996-12-17 | — | — | US | disclosed |
| WO-1996010999-A2 | LTA4 HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | disclosed |
| WO-1996011192-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | disclosed |